Real-World Analysis Of Treatment Patterns Examining Nab-Paclitaxel Plus Gemcitabine (Nab-P Plus G) Versus Folfirinox (Ffx) In First-Line (10 Treatment (Tx) Of Metastatic Pancreatic Adenocarcinoma (Mpac) In A Us Community Oncology Setting

e18130Background: In independent phase III trials, both nab-P + G and FFX demonstrated significantly better OS, PFS, and ORR than G alone as 1L tx for MPAC. Limited real-world data exist on the effectiveness of and treatment patterns associated with nab-P + G vs FFX for 1L tx of patients (pts) with MPAC, supporting the need for the current study. Methods: A retrospective cohort study was performed using fully de-identified data from a nationally representative electronic medical record platform of 1,300 community oncologists. Pts diagnosed with MPAC between 9/10/13 and 10/6/14 and received either nab-P+G or FFX as 1L tx were included. We calculated median time to treatment discontinuation (TTD) and estimated survival (ES), proxy for OS, using the Kaplan Meier method. We also assessed incidence of adverse events (AEs), utilization of supportive care, and incidence of regimen modifications and dose delays across the two groups. Lastly, we explored outcomes associated with sequencing 1L and 2L therapy. Resul...